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Abstract
Our group is interested in evaluating early eﬀects of dietary interventions on bone loss. Postmenopausal women lose bone following
reduction in estrogen which leads to increased risk of fracture. Traditional means of monitoring bone loss and eﬀectiveness of treatments
include changes in bone density, which takes 6 months to years to observe eﬀects, and changes in biochemical markers of bone turnover,
which are highly variable and lack speciﬁcity. Prelabeling bone with 41Ca and measuring urinary 41Ca excretion with accelerator mass
spectrometry provides a sensitive, speciﬁc, and rapid approach to evaluating eﬀectiveness of treatment. To better understand 41Ca technology as a tool for measuring eﬀective treatments on reducing bone resorption, we perturbed bone resorption by manipulating dietary
calcium in rats. We used 3H-tetracycline (3H-TC) as a proxy for 41Ca and found that a single dose is feasible to study bone resorption.
Suppression of bone resorption, as measured by urinary 3H-TC, by dietary calcium was observed in rats stabilized after ovariectomy, but
not in recently ovariectomized rats.
Ó 2007 Elsevier B.V. All rights reserved.
PACS: 82.80.Ms; 87.58.Xs; 82.39.Rt
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1. Introduction
Osteoporosis, a disease that is characterized by low bone
mass, warrants attention. In 2002, the estimated national
direct expenditure for osteoporotic hip fractures was
$18 billion. It is projected that the number of people with
osteoporosis will increase from 10,100,000 in 2002 to
12,000,000 and 13,900,000 in 2010 and 2020, respectively
[1]. Consequences of osteoporosis are potentially fatal as
an average of 24% of hip fracture in patients aged 50 and
over usually die within a year following fracture [1]. Management of osteoporosis is crucial because there are treatments, but no cure, for the disease.
*
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There are various ways to manage osteoporosis, including medications such as bisphosphonates and hormone
therapy, as well as dietary means such as calcium and vitamin D supplementation. There is a large body of evidence
to indicate that calcium supplementation has beneﬁcial
eﬀects on bone during the entire life span. During childhood and adolescence, calcium increases bone acquisition
that may ultimately protect against low bone mass and
fracture later in life. It has been calculated from a metabolic balance study that an increase of calcium intake from
an average of 920 mg/d to 1300 mg/d during adolescence
would increase net calcium retention by 112 mg/d [2]. This
translates to an additional 4% of skeletal mass accrual over
1 year if the increase in dietary calcium were maintained.
During adulthood, dietary calcium supplementation
reduces fractures and slows down age-related bone loss,
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possibly by replacing the daily excretory and cutaneous
losses that would otherwise have drained skeletal calcium.
The importance of adequate dietary calcium during adulthood has also been shown through an increase in bone
mineral density when hormone therapy was administered
in the presence of suﬃcient calcium [3].
The mechanism by which calcium exerts a positive
eﬀect on bone has been examined by kinetic studies. In a
randomized, cross over, study of calcium kinetics in adolescent girls, the increased retention seen on a high calcium
diet (47.5 ± 3.9 mmol/day) versus a low calcium diet
(21.5 ± 2.0 mmol/day) was due to an increase in absorbed
calcium and suppression of bone resorption without aﬀecting bone formation [4]. This is in contrast to another kinetics study in normal adults that assessed the response in
calcium metabolism to dietary calcium perturbation [5].
In this study, a high dietary calcium intake did not result
in an increase in absorbed calcium for all the subjects.
However, when absorbed calcium increased in some
subjects, bone resorption was decreased, while renal and
gastrointestinal calcium clearance were increased. A low
calcium intake (0.2 g/day) resulted in a reduction of
absorbed calcium, an increase in bone resorption rate,
and a decrease in renal and gastrointestinal rate constants,
possibly suggesting that an increase in parathyroid hormone (PTH) is the common mediating factor since PTH
exerts its action on the kidney, intestine, and bone.
There is emerging evidence that calcium functions as an
indirect regulator of remodeling of the skeleton [6]. During
bone remodeling, the bone mineral that is being released
after bone is resorbed is either recycled or used to counterbalance excretory losses. When dietary calcium intake is
low for a prolonged period of time, bone remodeling continues to be high, resulting in an increase in bone fragility.
Therefore, high dietary calcium reduces bone remodeling,
which results in an immediate reduction in fracture risk
before any changes in bone mass or bone balance are
detected [6].
Calcium status is a crucial factor in determining bone
health and fracture risk. Calcium status is diﬃcult to assess
because serum calcium levels are tightly controlled. Bone
mineral content (BMC) measured by dual X-ray absorptiometry (DXA) is a proxy for cumulative calcium status
because 99% of the body’s calcium is in the bones. Indirect
measures of bone metabolism which impinge on calcium
status include bone biochemical markers of turnover that
measure substances that are released by osteoblasts and
osteoclasts, as well as substances produced during the formation or breakdown of collagen, a main protein found in
bone. Although DXA is considered the gold standard for
assessing bone status, it is limited by the long lag time that
is required between measurements (6 months to years ) in
order to show changes in bone mineral density (BMD)
and BMC. In addition, biochemical markers of bone turnover have huge variation. Therefore, there is a need for a
more sensitive but yet direct method of assessing bone status in response to treatments. A direct method for assessing
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release of calcium from the skeleton uses a calcium isotopic
tracer to assess bone changes in response to treatments.
However, some calcium isotopic tracers have limitations
for use in humans due to their short half life or radioactive
nature. Fortunately, 41Ca has a long half life of 100,000
years and is safe for use in humans due to the low level
of radioactivity required. Recently, 41Ca has been proposed
as a tool in bone research [7]. However, there is much to
learn about designing studies and interpreting data for
optimizing 41Ca technology as a tool for assessing bone
metabolism. In order to further our understanding of
41
Ca technology, we utilized 3H-tetracycline (3H-TC) as a
proxy for 41Ca in an animal study, with the ultimate goal
of developing the use of urinary 41Ca appearance from
bone to directly measure bone resorption in humans. Previous studies have shown that upon injection of 3H-TC in
animals, it chelates with calcium and is incorporated into
the skeleton. During bone resorption, 3H-TC is released
in a form that cannot be reincorporated into the skeleton
[8]. Thus, urinary 3H-TC is thought to reﬂect bone
resorption.
The aim of our study was to use a single 3H-TC injection, as a proxy for 41Ca, to understand timing of label
incorporation and release when bone resorption was
manipulated by dietary calcium.
2. Experimental
Sixty-four ovariectomized (OVX) 6-month-old rats were
purchased from Harlan (Indianapolis, IN). All the rats
were fed an AIN 93 M diet [9] (Dyets Inc., Bethlehem,
PA) during the acclimation period at our animal research
facility. This is a standard semi-puriﬁed diet that uses
casein as the protein source and meets nutrient requirements except as adjusted for calcium. Each rat was dosed
with 30 uCi of 3H-TC. The early OVX rats were dosed with
3
H-TC within 1 month after OVX while the OVX stabilized
rats were dosed 3 months after OVX. Rats were randomized to receive either 0.2% calcium or 0.5% dietary calcium
treatment. The recommended calcium intake is 0.5% which
is the level in the standard diet and serves as the control.
The 0.2% calcium intake was selected to be marginally deﬁcient without inducing weight loss. Within each dietary calcium level, rats were further randomized according to time
of sacriﬁce (1 week, 1 month, 3 months, or 6 months).
There was no diﬀerence in average baseline weight among
groups. Urine and feces were collected for 2–4 days at 1
week, 1 month, 3 months, and 6 months post dose. Immediately after collection, urine samples were centrifuged at
4000 RPM for 20 min. The supernatants were stored in a
20 °C freezer. After all the metabolic collections for the
entire study were completed, urine samples were thawed
at room temperature and centrifuged again at 3000 RPM
for 20 min. The supernatants were analyzed for calcium
and 3H-TC content. Feces were ashed for 4 days at
600 °C, diluted with 0.5% Lanthanium Chloride to 25 mL
and analyzed for calcium. Whole skeletons were recovered
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by using Dermastid beetles (provided by Dr. Alan York,
Entomology Department, Purdue University) as described
by Hefti et al. [10] after the rats were sacriﬁced. The skeletons were separated into cortical-rich midshaft femur, trabecular-rich proximal tibia and L1-4, and the rest of the
skeleton. Bones were digested with nitric acid and brought
up to volume with nitric acid for the assessment of percent
3
H-TC present and 3H-TC labeling eﬃciency. Total calcium in bone, urine, and feces was measured by atomic
absorption spectrophotometry as previously described [4]
(A Analyst 300, Perkin Elmer). Urinary and skeletal 3HTC content were measured by scintillation counting (LS
6500, Beckman Coulter Inc., Fullerton, CA) using a single
labeled disintegration per minute (DPM) program.
Calcium balance was determined as follows:
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Percent H-TC present in bone was calculated as:
100%
 3 H-TC in boneðdpmÞ=3 H-TC dose given to ratðdpmÞ
3

H-TC labeling eﬃciency in bone was calculated as:

Percent3 H-TC in bone=Calcium content in boneðgramsÞ
Bone mineral density (BMD) was determined by dual
energy X-ray absorptiometry (Lunar DPX IQ 5455, Madison, WI) at the start of the study and again before sacriﬁce
at 1 week, 1 month, 3 months, and 6 months post dose to
assess change in BMD and total bone calcium. This study
was approved by the Purdue Animal Care and Use
Committee.
SAS statistical software (version 8.0, SAS Institute,
Cary, NC) was used for all analyses. Data were reported
as mean ± standard deviation, unless otherwise indicated.
Urinary 3H-TC, calcium balance, and percent calcium
retention were compared at all time points by repeated
measures analysis of variance with multiple comparisons
of the means using Tukey’s test. Constant variance and
normality assumptions were improved when 3H-TC in
bone and urine was transformed by taking the log of the
original data. Therefore, all analyses for 3H-TC in bone
and urine were based on log transformed data. Tukey’s test
was used for multiple comparisons when the diﬀerences in
mean were signiﬁcant. p values less than 0.05 were considered statistically signiﬁcant.
3. Results and discussion
The eﬀect of calcium intake on calcium balance over
time is shown in Fig. 1. In an overall statistical model, rats
that were fed the 0.5% calcium diet had signiﬁcantly higher
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Fig. 1. Eﬀects of the level of dietary calcium on calcium balance (mg
calcium/day) in early OVX and OVX stabilized rats. Each line represents
the mean ± SD values of 4–16 rats, depending on the time of urine and
feces collection. Asterisks indicate dietary calcium eﬀect *p < 0.05.

calcium balance (p < 0.005) and percent calcium retention
(p = 0.052) up to 6 months post dose, but this was driven
by the rats stabilized to ovariectomy, as no time point
was statistically signiﬁcant in the early OVX rats. Rats
fed adequate calcium were in net positive balance, whereas
rats fed low calcium intakes were in negative balance at
1 month and in positive balance by 3 months. Rats fed
the 0.5% calcium diet excreted more calcium in the urine
and feces than rats fed the 0.2% calcium diet. Calcium
excretion over time is shown in Fig. 2. Rats fed the 0.5%
calcium diet consumed 2.5 times more calcium and
excreted approximately 2.5 times more calcium in the feces
and 1.4 times more calcium in the urine than rats fed the
0.2% calcium. Urinary calcium loss accounted for 3–6%
of calcium intake in rats.
Bone resorption, as measured by urinary 3H-TC, is
shown in Fig. 3. At 1 month post dose, higher calcium
intakes signiﬁcantly (p = 0.013) suppressed bone resorption in the OVX stabilized rats. The lack of a signiﬁcant
diﬀerence in urinary 3H-TC due to calcium intake at 6
months (p = 0.2) despite a greater diﬀerence in means than
at 1 month, which was statistically signiﬁcant, was
undoubtedly due to loss of power as rats were sacriﬁced

C. Weaver et al. / Nucl. Instr. and Meth. in Phys. Res. B 259 (2007) 790–795
Calcium intake

120

Fecal calcium

mg calcium/day

100

Urinary calcium

80
60
40
20
0
0

1

2

3

4

5

6

Months post dose
Fig. 2. Calcium intake, fecal and urinary calcium excretion of a
representative group (OVX stabilized rats on 0.5% calcium) of rats over
time (n = 4 per data point, mean ± SD).

would lead to a diﬀerence of 5.6% skeletal loss per year due
to the dietary calcium levels tested here, which is a substantial diﬀerence in loss of skeleton. The observation that
higher dietary calcium suppressed bone resorption in rats
stabilized to OVX, but not in the early OVX rats, is consistent with data in humans which show that dietary calcium
does not aﬀect bone density during peri-menopause when
bone turnover is dominated by hormones [11].
Dietary calcium had no eﬀect on 3H-TC retention or
labeling eﬃciency at any bone site in all groups. BMD
decreased from baseline to 1 week post dose for all rats
(p < 0.0001) as expected for the ﬁrst 3 months following
ovariectomy due to estrogen deﬁciency. The reduction
was more pronounced for rats on the 0.2% than the 0.5%
calcium diet (p = 0.03) (Fig. 4). Overall, there was a cumulative eﬀect of diet on BMD (p = 0.0577), with rats on 0.2%
calcium diet having lower BMD. The amount of total bone
calcium loss decreased over time as rats became stable to
ovariectomy (Fig. 5). Rats that were fed the 0.2% calcium
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Fig. 4. Bone mineral density of rats over time, controlling for BMD at
baseline. Each line represents the mean ± SE values of 4 rats. There was a
cumulative eﬀect of diet on BMD (p = 0.0577), with rats on 0.2% calcium
diet having lower BMD.
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(n = 12 rats/group at 1 month and n = 4 rats/group at 6
months). The lack of dietary eﬀect at 3 months post dose
for either 3H-TC excretion or calcium balance is inexplicable and inconsistent with the overall results. Because we
know the total skeletal calcium content of the rats
(3448 ± 302 and 3312 ± 358 mg Ca for early and stabilized
OVX rats, respectively, at 1 month) and we know daily calcium loss, we can predict % skeletal calcium loss over time
to determine clinical relevance. The calcium loss at 1 month
post dose was 1.54 ± 0.73 mg Ca/day compared to
2.01 ± 0.68 mg Ca/day for rats fed 0.5% calcium diets. This

600

Total Ca lost (mg/d)

Fig. 3. Urinary 3H-TC of rats that received 0.2% Ca versus 0.5% Ca. Each
line represents the mean ± SD values of 4–16 rats (depending on urine
collection time points). *0.2% Ca diet diﬀers from 0.5% Ca diet, p < 0.05.
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Fig. 5. Eﬀects of dietary calcium levels on total bone calcium lost. Each
line represents the mean ± SD values of 16 rats. The eﬀect of dietary
calcium on bone calcium loss was signiﬁcant at eﬀect *p < 0.05. The rats
are the same as those in Fig. 4; therefore, reference to months post OVX
for a given age can be determined from Fig. 4.
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diet had signiﬁcantly higher total bone calcium loss than
rats fed the 0.5% calcium diet as expected from urinary
3
H-TC and calcium balance.
Higher dietary calcium suppresses bone resorption
through the parathyroid hormone/vitamin D axis of
homeostatic control. High dietary calcium suppresses
parathyroid hormone release which slows conversion of
25-hydroxyvitamin D to 1,25-dihydroxyvitamin D. This
reduces bone resorption and active calcium absorption,
and increases urinary calcium loss. Consequently, calcium
retention diﬀered between rats fed high and low calcium
intakes in the rats stabilized to OVX, but in the early
OVX rats, eﬀects of loss of estrogen on bone resorption
outweighed eﬀects due to dietary calcium. Stabilized
OVX rats were older animals than the early OVX animals
and could have had lower ability compared to younger animals to adapt to changes in serum calcium in response to
diet. Age and estrogen deﬁciency should combine to reduce
the ability to adapt with time and would lessen diﬀerences
between high and low calcium intake. However, Talbott
et al. [12] showed little diﬀerences in response to dietary
calcium with age. The eﬀects of low dietary calciuminduced bone resorption have been shown using urinary
3
H-TC to occur as early as 6 hours after the initiation of
a low calcium diet [8]. Interestingly, Talbott et al. [12] demonstrated an increase in urinary 3H-TC levels only during
the ﬁrst 3 weeks of a 9 week period of dietary calcium
restriction (0.1% calcium) in 20 and 48 week-old rats. These
rats started receiving chronic 3H-TC labeling over a 6 week
period when they were 12 and 40 weeks old. Biochemical
markers of bone resorption (pyridinoline and deoxypyridinoline) showed dietary eﬀects up to 6 weeks. If the eﬀect
of diet is transient, the timing for measuring eﬀects on bone
resorption is crucial. Urinary 3H-TC increased when the
diets of 2 month-old male rats were changed from 1.1 g
Ca/100 g dry weight to 0.2 g Ca/100 g dry weight in an
acute setting [13]. Others [14,15] have also demonstrated
changes in urinary 3H-TC levels in an acute setting during
dietary interventions that lasted for 10 days. There is a
paucity of data that examines urinary 3H-TC in a chronic
setting. In our study the eﬀect of dietary calcium on calcium balance and bone calcium loss and BMD were significant at 6 months, but the eﬀect of dietary calcium on
urinary 3H-TC excretion is equivocal because of lack of
power beyond 1 month post dose. A further limitation is
that in rodents, a relatively small proportion of dietary calcium is being excreted in the urine of rats (3–6% in rats versus 14% in humans) [4]. Thus, changes in urinary calcium
in rats have minimal eﬀect on calcium balance.
In this study, we are unable to resolve whether the eﬀects
of dietary calcium on bone turnover are transcient or
chronic. Biochemical markers of bone turnover have a sustained response to other interventions such as estrogen and
bisphosphonate therapies that perturb bone turnover that
result in diﬀerences in BMD [16,17]. It is unlikely that a
lack of signiﬁcant diet eﬀect on urinary 3H-TC beyond 1
month post dose was due to draining of 3H-TC from the

skeleton as a result of calcium deﬁcient diet, as proposed
by Talbott et al. [12], because 3H-TC could still be detected
in the urine and skeleton up to 6 months post dose. It is
also unlikely that a lack of diet eﬀect on urinary 3H-TC
excretion beyond 1 month was due to the single 3H-TC
dosing regimen, because chronic pre-labeling [12] showed
similar transient results. It has been reported that repeated
exposure to the labeled material during early rapid skeletal
growth period, such as in utero or shortly after birth, is
required in order to study the normal behavior of calcium
in adult rat skeleton [13,18]. Labeling the skeleton of older
animals is not usually performed due to the lower rate of
bone turnover. However, the present study demonstrates
that labeling 6–9 month-old OVX rats with a single dose
of 30 uCi of 3H-TC is feasible to study bone resorption.
Further research is needed with increased power to evaluate chronic eﬀects of diet on urinary 3H-TC. It is logical
that eﬀects of dietary calcium on indices of bone turnover
would parallel changes in calcium balance and bone mineral content.
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